New collaboration with RESPINE
Last month we have started a collaboration with the RESPINE cel thearpy in clinical trial phase, to increase the impact of both projects and to support each other during the project life time and after. Many of our consortium partners are involved in both projects including Université de Nantes, University of Montpellier, NUIG, UCBM. Read more about their project below and on their website.
.
.
« Innovative strategies for chronic low back treatment »
Nowadays, Chronic low back pain (LBP) is a major public health issue in Europe. Indeed, this disabling condition affects several millions of Europeans. The most common cause of chronic low back pain is the degenerative disc disease (DDD). DDD, a progressive deterioration of the intervertebral disc, occurs when the cells of the intervertebral disc age, desiccate and are no longer regenerated nor replaced by new cells. If the conventional treatments (e.i. analgesics and physiotherapy) fail, there is little alternative, except surgery (discectomy). This is why, Professor Jorgensen director of the Institute of Regenerative Medicine and Biotherapies at the University Hospital of Montpellier, France, initiated the study RESPINE, a phase 2/3 European clinical trial, which consists of demonstrating the therapeutic interest of a new cell therapy treatment. This innovative therapy is based on a single injection of mesenchymal stem cells harvested from a healthy donor’s bone marrow. This treatment could potentially trigger disc regeneration and durably reduce pain, while avoiding spine surgery. Overall, 112 patients are planned to enroll in 9 hospital centers in France (Montpellier, Paris-St Antoine, Paris-Cochin, Nantes), Spain (Barcelona, Navarra, Valladolid), Italy (Rome) and Germany (Halle). The RESPINE trial has started in spring 2019. To date, over forty patients have been included.
